Shannon Oda, PhD

Shannon  Oda,  PhD

Academic Title: Assistant Professor, Pediatrics

Research Title: Principal Investigator

"My passion is to develop new cancer therapy options for patients by harnessing the power of the immune system to target and destroy cancer cells. Our research focuses on T cell immunotherapy, and we have identified several obstacles that inhibit immune cells from effectively eradicating tumors. We invent new ways to engineer T cells to overcome these obstacles and improve immunotherapy of blood cancers and solid tumors. We are excited to advance innovative, safer therapies, and improve outcomes for cancer patients."

  • Biography

    • Related Pages

    • About My Work

      We develop engineering strategies that enable T cells to overcome obstacles in the tumor microenvironment and mount a more powerful, durable and sustained attack on cancer cells.

  • Publications

    Other Publications

    • Anderson KG, Voillet V, Bates BM, Chiu EY, Burnett MG, Garcia NM, Oda SK, Morse CB, Stromnes IM, Drescher CW, Gottardo R, Greenberg PD
      Engineered Adoptive T-cell Therapy Prolongs Survival in a Preclinical Model of Advanced-Stage Ovarian Cancer.
      31337659 Cancer immunology research, 2019 Sept. : 7(9)1412-1425 PMCID:PMC6726582
    • Oda SK, Daman AW, Garcia NM, Wagener F, Schmitt TM, Tan X, Chapuis AG, Greenberg PD
      A CD200R-CD28 fusion protein appropriates an inhibitory signal to enhance T-cell function and therapy of murine leukemia.
      29042364 Blood, 2017 Nov 30 : 130(22)2410-2419 PMCID:PMC5709784
    • Hu J, Oda SK, Shotts K, Donovan EE, Strauch P, Pujanauski LM, Victorino F, Al-Shami A, Fujiwara Y, Tigyi G, Oravecz T, Pelanda R, Torres RM
      Lysophosphatidic acid receptor 5 inhibits B cell antigen receptor signaling and antibody response.
      24890721 Journal of immunology (Baltimore, Md. : 1950), 2014 Jul 1 : 193(1)85-95 PMCID:PMC4128188
    • Mourich DV, Oda SK, Schnell FJ, Crumley SL, Hauck LL, Moentenich CA, Marshall NB, Hinrichs DJ, Iversen PL
      Alternative splice forms of CTLA-4 induced by antisense mediated splice-switching influences autoimmune diabetes susceptibility in NOD mice.
      24494586 Nucleic acid therapeutics, 2014 April : 24(2)114-26
    • Oda SK, Strauch P, Fujiwara Y, Al-Shami A, Oravecz T, Tigyi G, Pelanda R, Torres RM
      Lysophosphatidic acid inhibits CD8 T cell activation and control of tumor progression.
      24455753 Cancer immunology research, 2013 Oct. : 1(4)245-55 PMCID:PMC3893823
    • Kerkvliet NI, Steppan LB, Vorachek W, Oda S, Farrer D, Wong CP, Pham D, Mourich DV
      Activation of aryl hydrocarbon receptor by TCDD prevents diabetes in NOD mice and increases Foxp3+ T cells in pancreatic lymph nodes.
      20174617 Immunotherapy, 2009 July : 1(4)539-47 PMCID:PMC2823486


Research Description

Dr. Shannon Oda received a Ph.D. in Immunology from the University of Colorado Anschutz Medical Campus/National Jewish Health and completed her postdoctoral training with Dr. Philip Greenberg at the Fred Hutchinson Cancer Center. She has received several awards, including the Evergreen Fund Award and the LLS Career Development Program Special Fellow Award, and has been invited to give talks internationally. Dr. Oda joined the Seattle Children’s Research Institute in 2020, where she is an Assistant Professor at the Ben Towne Center for Childhood Cancer Research and the University of Washington School of Medicine.


Research Focus Area

Cancer, Immunology, Novel Therapeutics